The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the FDA seeking to expand the indication of Edurant… read more.
A study involving more than 745,000 adolescents from 41 countries across Europe and North America identified an increase in the amount of teenagers who underestimate their body weight…. read more.
Nearly half of parents who relied on formula to feed their babies during the infant formula shortage last year resorted to potentially harmful feeding methods, according to a survey from… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Mircera… read more.
The make-up and volume of gut bacteria in toddlers at 3.5 years old is predictive of body mass index (BMI) at age 5, irrespective of whether they are… read more.
Bayer and its development partner MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA) announced that the first patient has been enrolled in the Phase II/III… read more.
Fennec Pharmaceuticals Inc.has announced Pedmarqsi– known as Pedmark in the U.S. – was granted marketing authorization by the European Commission. Pedmarqsi is the first and only approved therapy… read more.
“Kangaroo mother care,” involving lengthy skin-to-skin contact between a mother and her prematurely born or low birth weight child, affects significantly the child’s chances of survival. Researchers reported… read more.
Pre-term and low birthweight infants have fewer fractures in childhood than full-term and normal-weight newborns, according to a new a study from the University of Eastern Finland and… read more.
Portable ultrasound devices could provide an alternative to x-ray machines for diagnosing forearm fractures in children in a move that could alleviate waiting times for families in hospital… read more.
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year… read more.
Takeda announced that the FDA has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
